Rapid decline in bone turnover markers but not bone mineral density in acromegalic patients after transsphenoidal surgery
-
- Tamada Daisuke
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Kitamura Tetsuhiro
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Onodera Toshiharu
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Tabuchi Yukiko
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Fukuhara Atsunori
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Oshino Satoru
- Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Saitoh Youichi
- Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Hamasaki Toshimitsu
- Department of Biomedical Statistics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Otsuki Michio
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Shimomura Iichiro
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
Search this article
Abstract
Growth hormone (GH) and insulin-like growth factor-I (IGF-I) play important roles in maintaining bone metabolism and bone mineral density (BMD) in adulthood, in addition to stimulating longitudinal bone growth in childhood. However, information on the effect of GH excess on bone metabolism and BMD is incomplete and requires further analysis. The aim of this study is to clarify the effect of rapid decline in GH levels after transsphenoidal surgery (TSS) on bone metabolism in acromegalic patients. In this prospective study, 22 patients (11 males and 11 females) with active acromegaly underwent TSS. Bone formation marker (serum bone alkaline phosphatase: BAP), bone resorption marker (urinary type I collagen cross-linked N-telopeptide: urinary NTx) and BMD were measured before and at 3 and 12 months after TSS. BAP was significantly decreased at 12 months after TSS, but not at 3 months. Urinary NTx was significantly decreased at 3 and 12 months after TSS. BMD did not change after TSS. In conclusion, the rapid fall in GH level after TSS had no effect on BMD for up to 12 months after TSS despite the decrease in markers of bone formation and resorption.
Journal
-
- Endocrine Journal
-
Endocrine Journal 61 (3), 231-237, 2014
The Japan Endocrine Society
